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Abstract 
Purpose: For optimal management of ductal carcinoma in situ (DCIS), reproducible histopathological 
assessment is essential to distinguish low-risk from high-risk DCIS. Therefore, we analyzed interrater 
reliability of histopathological DCIS features and assessed their associations with subsequent ipsilateral 
invasive breast cancer (iIBC) risk. 
Methods: Using  a case-cohort design, reliability was assessed in a population-based, nation-wide 
cohort of 2,767 women with screen-detected DCIS diagnosed between 1993-2004, treated by breast 
conserving surgery with/without radiotherapy (BCS+/-RT) using Krippendorff’s alpha (KA) and Gwet’s 
AC2 (GAC2). Thirty-eight raters scored histopathological DCIS features including grade (2-tiered and 
3-tiered), growth pattern, mitotic activity, periductal fibrosis and lymphocytic infiltrate in 342 
women. Using majority opinion-based scores for each feature,  their association with subsequent 
iIBC-risk was assessed using Cox regression. 
Results: Interrater reliability of grade using various classifications was fair to moderate, and only  
substantial for grade 1 versus 2+3 when using GAC2 (0.78). Reliability for growth pattern (KA 0.44, 
GAC2 0.78), calcifications (KA 0.49, GAC2 0.70) and necrosis (KA 0.47, GAC2 0.70) was moderate using 
KA and substantial using GAC2; for (type of) periductal fibrosis and lymphocytic infiltrate fair to 
moderate estimates were found and for mitotic activity reliability was substantial using GAC2 (0.70).  
Only in patients treated with BCS-RT,  high mitotic activity was associated with a higher iIBC-risk in 
univariable analysis (Hazard Ratio (HR) 2.53, 95% Confidence Interval (95%CI) 1.05-6.11); grade 3 
versus 1+2 (HR 2.64, 95%CI 1.35-5.14) and a cribriform/solid versus flat epithelial 
atypia/clinging/(micro)papillary growth pattern (HR 3.70, 95%CI 1.34-10.23) were independently 
associated with a higher iIBC-risk.   
Conclusions: Using majority opinion-based scores, DCIS grade, growth pattern and mitotic activity are 
associated with iIBC-risk in patients treated with BCS-RT, but interrater variability is substantial. Semi-
quantitative grading, incorporating and separately evaluating nuclear pleomorphism, growth pattern 
and mitotic activity, may improve the reliability and prognostic value of these features. 
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Background 
Ductal carcinoma in situ (DCIS) of the breast is a non-obligate precursor of invasive breast 
cancer (IBC). Since the introduction of organized population-based breast screening, the incidence of 
DCIS has increased manyfold [1–3]. Although DCIS is almost always treated to avoid progression to IBC, 
this has not led to a reduced IBC incidence. Breast screening programs are therefore criticized by some 
for being associated with overdiagnosis and overtreatment of DCIS [4–6]. It has been reported that a 
large proportion of untreated DCIS will not progress to IBC [7,8]. Ryser et al. reported a 10-year net 
risk of ipsilateral IBC (iIBC) of 12.2% (95% Confidence Interval (95%CI) 8.6-17.1%) for women with DCIS 
grade 1/2 and 17.6% (95%CI 12.1-25.2%) for grade 3 [8]. Although based on selected patients, these 
results underline that at least some DCIS lesions have a low risk of progression and may thus be 
overtreated. However, reliably distinguishing high from low risk DCIS to guide treatment is still 
challenging. 
Many studies have tried to find histopathological markers that could predict progression of 
DCIS [9,10]. So far, no single marker ended up being used in clinical practice due to lack of conclusive 
evidence of predictive ability, in part due to suboptimal biased study designs in particular due to 
insufficient handling of confounders and poorly described study groups [10]. Especially grade has been 
extensively studied as a biomarker for the invasive potential of DCIS. The use of many different grading 
systems with partly unclear criteria and often only poor to modest interrater reliability makes it 
difficult to evaluate the role of grade in risk stratification [11–21].  
In addition, various studies have assessed reproducibility of histopathological evaluation of 
DCIS lesions. Unfortunately, these studies were frequently based on highly selected case sets, assessed 
by expert breast pathologists often after having received instructions or tutorials beforehand and using 
reference diagnoses without follow-up data [17,18,22–28]. The interpretation of results and 
evaluation of potential bias is further complicated by inadequate reporting [29]. 
This study assesses the interrater reliability of various histopathological features in DCIS in a 
setting which as closely as possible reflects daily practice. We subsequently evaluate whether these 
7 
 
features, based on a more robust majority opinion of 38 raters, are associated with risk of development 
of subsequent iIBC. 
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Methods  
Patient selection 
We assembled a population-based, nation-wide cohort of screen-detected primary and pure 
DCIS, treated with breast conserving surgery with or without adjuvant radiotherapy (BCS+/-RT) 
between January 1st 1993 and December 31st 2004, by linkage of data from the Netherlands Cancer 
Registry (NCR) with data from the Dutch breast cancer screening program [30]. From 1989, the Dutch 
biennial screening program was gradually introduced, inviting women aged 50-69 years and from 1998 
aged 50-75 years. Screen-detected DCIS was defined as DCIS detected within 30 months after a first or 
subsequent positive screening examination. The cohort was supplemented with data from the 
nationwide network and registry of histology and cytopathology in the Netherlands (PALGA) [31]. 
Information on age and date at diagnosis, treatment, and if applicable subsequent iIBC and vital status 
was provided by the NCR (follow-up data available until January 1, 2011). Patients diagnosed with a 
prior malignancy, other than non-melanoma skin cancer, were excluded. The review boards of the 
NCR, PALGA and the Dutch breast cancer screening organization approved this study.  
 
Interrater reliability analysis 
We first assessed the interrater reliability of histopathological DCIS features in this cohort using 
a case-cohort design [32]. From the cohort of 2,767 women, we randomly sampled 357 women 
(subcohort; 13%) and additionally selected all 177 patients who subsequently developed an iIBC but 
were not included in the random sample for a total of 534 patients. Fig. 1 shows the selection of 
patients with exclusions at pathology report review (n = 27) and slide review (n = 76). Slide review was 
based on freshly cut slides stained with hematoxylin and eosin and in case of uncertainty about the in-
situ nature of the lesion also with cytokeratin 14 by EJG (clone LL002; 1/3200 dilution, 32 minutes at 
370C + amplification, Neomarkers / Thermo Scientific). 
For 353 patients the diagnosis of pure DCIS could be confirmed and from each lesion a single 
slide was selected with the highest quantity of DCIS. These slides were digitized using an Aperio AT2 
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scanner (Leica Biosystems) at 20x magnification and uploaded on an online viewing platform 
(https://www.slidescore.com/). For each DCIS lesion a scoring form (Supplementary methods) was 
built-in with the items: DCIS diagnosis, grade (2- and 3-tiered), growth pattern and mitotic activity of 
DCIS, calcifications, necrosis, periductal fibrosis and lymphocytic infiltrate.   
European raters with varying expertise were invited to participate in the study. Each rater was 
assigned a study set of 146 cases to score independently, blinded to subject information. Raters were 
not given instructions regarding the (interpretation of) histopathological features and were requested 
to score as they would in daily practice to provide an unbiased baseline measure of reliability. Further 
details on rater selection, participation and the scoring process are described in Supplementary 
methods.  
 
Statistical analysis  
In total 11 patients were excluded from reliability analysis because >50% of raters considered 
their lesion as no DCIS /not assessable (n = 5) or >25% commented on suboptimal slide quality (n = 6). 
If DCIS was not confirmed, any scores for following histopathological features were ignored. Scores for 
type of fibrosis were only considered when periductal fibrosis was present according to the majority 
opinion. Raters were excluded for the analysis of single histopathological features when they scored 
an item as ‘not assessable’ in >50% of their study set.  
Krippendorff’s alpha (KA), Gwet’s AC2 (GAC2) and percentage agreement were calculated to 
assess interrater reliability (‘not assessable’ scores were excluded) [33,34]. KA and GAC2 are applicable 
to studies involving nominal/ordinal data and multiple raters scoring different subsets. A weighted 
analysis using linear weights was used for ordinal variables with >2 categories. Interpretation was 
performed according to Landis and Koch [35]. Recategorization of grade, periductal fibrosis, and 
lymphocytic infiltrate was undertaken during analysis to evaluate reliability using different cut-offs.  
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For the analysis of subsequent iIBC risk an additional 10 patients were excluded, because >25% 
of the raters considered IBC to be present adjacent to DCIS (n=8) or because the patient underwent a 
mastectomy before developing iIBC (n=2). For a detailed comparison of clinical characteristics between 
in- versus excluded patients see Supplementary Table 1. 
Associations of histopathological features, treatment, age at diagnosis and period of diagnosis 
(1993-1998, reflecting the screening implementation phase, versus 1999-2004, reflecting full 
nationwide coverage) with risk of iIBC was assessed using Cox models. Analyses were performed 
irrespective of treatment as well as separately for BCS alone and BCS+RT. Interactions with treatment 
were also considered. Proportional hazard assumptions (PHA) were tested using residual-based and 
graphical methods. In case the PHA was violated, a time factor was added, and the associations were 
estimated for different time-periods (i.e. for the first 5 years and after 5 years). For the 
histopathological features the majority opinion, i.e. the most frequently assigned category, was used 
in the analysis (‘not assessable’ scores were excluded). In case of equal frequencies, the presence of a 
histopathological feature was chosen over absence, the highest grade, the most complex growth 
pattern (i.e. cribriform/solid), many over sparse mitoses, prominent over subtle presence for 
periductal fibrosis and lymphocytic infiltrate and the least common type of fibrosis (i.e. myxoid). 
Clinicopathological factors were entered in multivariable models including treatment, based on a P 
value ≤0.15 in univariable analyses. Barlow’s inverse probability weights were used to adjust the partial 
likelihood function for case-cohort analysis with robust variance estimation [32]. Fit of non-nested 
models was compared using Akaike's and Bayesian information criteria. Two-sided P values ≤0.05 were 
considered statistically significant. All statistical analyses were performed using Stata/SE (version 13.1, 
Statacorp).  
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Results 
Interrater reliability 
The mean number of scores per slide was 14 (range 12-15) (Supplementary Table 2). The raters 
consisted of a mixed group (Supplementary Table 3), about half of them working in the Netherlands 
and half in other European countries within a wide range of laboratories regarding size and degree of 
specialization. Forty-seven percent of raters were members of the European Working Group of Breast 
Screening Pathologists. The diagnosis of DCIS was confirmed in 98.6% of the patients based on the 
majority opinion.  
The interrater reliability for the 3-tiered grading system (grade 1, 2 or 3), the most commonly 
used histopathological feature, was only fair (KA 0.34; 95%CI 0.30-0.39) to moderate (GAC2 0.52; 
95%CI 0.50-0.55; Table 1). Using a 2-tiered grading system (either low versus high grade or grade 1+2 
versus grade 3) did not improve reliability. When the 3-tiered grading was recategorized into a 
category for grade 1 and a category for grade 2+3 combined, the reliability was substantial using GAC2 
(0.78; 95%CI 0.74-0.82).  
Comparable moderate (KA) to substantial (GAC2) reliability was found for growth pattern, 
necrosis and calcifications, which are all features assessed in daily practice within the context of DCIS. 
A striking discrepancy in reliability was found for the assessment of mitotic activity with only fair 
reliability when considering KA (0.24) but substantial reliability based on GAC2 (0.70). In a 3-tiered 
system (absent, subtle or prominent presence) lymphocytic infiltrate showed moderate reliability, 
which was slightly better than the interrater reliability for periductal fibrosis. Recategorization, 
comparing periductal fibrosis presence with absence led to a moderate reliability (GAC2 0.53). 
 
Risk of subsequent iIBC after DCIS 
Subcohort patients were diagnosed with DCIS at a median age of 58.4 (interquartile range 
53.4-64.0) and treated by BCS alone in 40.5% (87 patients) and by BCS+RT in 59.5% (128 patients). 
After a median follow-up of 11.2 years (interquartile range 8.6-14.1), 20 patients developed an iIBC in 
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the subcohort. DCIS was assigned grade 1 in 10.7%, grade 2 in 53.5% and grade 3 in 35.8%, based on 
the majority opinion. Median time to iIBC was 5.3 years (interquartile range 3.3-7.6 years). Table 2 
shows clinicopathological characteristics of the subcohort and of all patients who developed an iIBC.  
In univariable analysis, patients treated with BCS alone had a much higher risk of iIBC than 
patients treated with BCS+RT with a Hazard Ratio (HR) of 4.80 (95%CI 2.49-9.24) in the first 5 years and 
a HR of 2.47 after 5 years (95%CI 1.42-4.30; Supplementary Table 4). In patients treated with BCS alone, 
grade 3 (versus grade 1+2 combined), a cribriform/solid growth pattern (versus flat epithelial atypia 
(FEA), clinging and (micro)papillary growth pattern) and mitotically active DCIS (versus DCIS with low 
mitotic activity) was also associated with a higher iIBC risk, whereas in patients treated with BCS+RT 
these associations were not found. In univariable analysis, a significant interaction with treatment was 
found for grade 3 versus 1+2 (P=0.028) and for growth pattern (P=0.023). 
In multivariable analysis a model which, besides treatment, included grade 3 versus grade 1+2 
and growth pattern (cribriform and solid versus FEA, clinging and (micro)papillary) best predicted the 
risk of developing iIBC in patients treated with BCS alone, while grade and growth pattern were not 
associated with iIBC risk in patients treated with BCS+RT (Table 3). The risk of developing iIBC did not 
differ between patients with DCIS grade 1/2 and FEA, clinging or (micro)papillary growth pattern who 
were treated with BCS alone or BCS+RT. Fig. 2 shows cumulative risk of iIBC based on categories 
derived from this model.  
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Discussion 
To the best of our knowledge, this is the first study combining a comprehensive interrater 
reliability study in DCIS, reflecting daily practice as closely as possible, with an analysis of iIBC risk based 
on the majority opinion of a large group of raters. This approach minimizes the muddling effect of 
interrater variability and subjectivity on the evaluation of the prognostic value of histopathological 
features. 
In univariable analysis, patients treated with radiotherapy after BCS had a strongly reduced 
risk of iIBC compared to those treated by BCS alone, as was already shown previously [30,36,37]. Also 
grade 3 (versus grade 1+2 combined), a high mitotic activity and a cribriform/solid growth pattern 
(versus FEA, clinging or (micro)papillary growth pattern) were associated with increased iIBC risk in 
patients treated with BCS alone. In multivariable analysis however, only grade 3 (versus grade 1+2) 
and a cribriform/solid growth pattern were independently associated with an increased iIBC risk. 
Mitotic activity did not add any predictive value to grade 3 versus 1+2 and growth pattern in a 
multivariable model, though this is likely due to collinearity with grade. Another important finding in 
our study is that no histopathological features were associated with iIBC risk in the patients treated 
with BCS+RT. Although women in our study were not randomized for treatment arm, this finding may 
suggest that radiotherapy neutralizes the effect of these classical histopathological features. This is 
also in line with the fact that within the large randomized controlled trials of RT in DCIS no subgroup 
could be identified without RT benefit [36]. 
So far, grade is the sole histopathological feature in DCIS that is used in clinical practice and 
also has an impact on eligibility in the context of clinical trials investigating the safety of active 
surveillance in low risk DCIS [38–40]. In general, only women over the age of 45 or 50 with screen-
detected calcifications associated with DCIS grade 1 or grade 2 are eligible in these trials. A three-tiered 
grading system is used for this selection purpose. Our study supports the rationale to distinguish 
between grade 1+2 versus grade 3 as DCIS grade 3 is independently associated with an increased risk 
of iIBC in patients treated with BCS alone. Unfortunately, the interrater reliability of assessing grade 
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using either a 3-tiered grading system (grade 1, 2 or 3) or a 2-tiered system differentiating grade 1+2 
combined versus grade 3 was only fair when considering KA and at best moderate based on the GAC2. 
The interrater reliability for growth pattern was moderate (KA) to substantial (GAC2). The 
predictive ability of grade and growth pattern has been intensively studied previously, with conflicting 
results [10]. Factors such as substantial interrater variability, grading system used, bias in designs and 
relying on histopathological assessments of a single pathologist’s opinion may have resulted in these 
different findings [10]. Interrater reliability based on GAC2 was higher overall, when histopathological 
features showed strongly skewed distribution and when agreement was already very high (i.e. grade 
1 versus 2+3, growth pattern and mitotic activity). Under these circumstances a GAC2 test may result 
in more accurate reliability coefficients, as was previously shown in comparison with Cohen’s kappa, 
which overestimates the concordance attributed due to chance alone in these situations leading to 
lower reliability coefficients [41]. 
In view of the prognostic value and interrater reliability observed in our study, it is 
questionable whether it is safe to base clinical treatment decisions solely on the assessment of classical 
histopathological features. Here, we propose four strategies that may improve risk stratification in 
DCIS.  
Within the context of DCIS the three features with reasonable prognostic value (grade 1+2 
versus 3, growth pattern and mitotic activity) are currently used in many grading systems, but without 
clear definitions and rules about how to value each feature. We therefore firstly would suggest to 
objectify histological grading by using a numerical semi-quantitative scoring system which separately 
evaluates each of these features, analogous to the modified Bloom and Richardson grading system for 
IBC [42,43]. Dichotomous scoring systems may further improve reliability and prognostic value and 
should be further explored evaluating different cut-offs [44,45]. 
Secondly, performing additional immunohistochemistry to assign specific DCIS profiles may 
add prognostic value, possibly only in subsets of patients (i.e. grade 2). Previously, associations were 
reported of human epidermal growth factor receptor 2 (HER2)-positive, estrogen receptor (ER)-
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negative DCIS and DCIS with high cyclooxygenase 2, p16 and Ki-67 levels with increased iIBC risk 
[9,10,46,47]. These markers would be good candidates for further exploration. Automated scoring 
within this context may result in more standardized and objective assessment [48–51]. Previously, a 
3-tiered grading system in DCIS, combining nuclear grade according to the Van Nuys criteria with 
automated Ki-67 count, was reported to show excellent correlation with immunohistochemical 
markers of reported biological relevance such as ER and HER2 [9,46,47,50].  
Thirdly, alternative approaches using pathology information such as artificial intelligence-
based methods should also be considered in search for clinically relevant biomarkers in DCIS [52]. 
Recently, others have developed a whole slide image-based machine learning model, which accurately 
predicted the risk of an invasive or in situ recurrence and significantly outperformed traditional 
clinicopathological variables [53]. 
Lastly, besides pathology, other criteria could also be incorporated in clinical decision schemes, 
e.g. as in current active surveillance trials requiring DCIS to be screen-detected based on calcifications 
only without clinical symptoms and diagnosed on representative vacuum-assisted biopsies [38–40]. 
Our study had several limitations. From our study population each rater scored a different 
subset of patients. Therefore, we were not able to analyze the association of histopathological DCIS 
features with iIBC risk per rater or grading system used and to study the effect of interrater variability 
on risk stratification. However, the resulting immense workload would probably have caused major 
rater-dropout. Also tissue slides were digitally assessed using research technology producing images 
of somewhat lower resolution. This may have led to difficulty of assessing histopathological features 
requiring great detail, such as mitotic activity. Our reliability study was nonetheless performed under 
conditions as close as possible to clinical practice, as a large set of non-selected DCIS cases from a 
population-based cohort were reviewed by a large group of raters with varying levels of expertise 
without provision of instructions or tutorials beforehand. And lastly, data on margin status and DCIS 
lesion size, factors potentially associated with the risk of iIBC, was not available [10,46,47,54]. 
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Conclusions 
We evaluated the prognostic value of histopathological DCIS features to inform risk 
stratification using a unique, combined approach. Our study showed substantial interrater variability 
in the classification of histopathological DCIS features, while using rater majority opinions, minimizing 
the muddling effect of interrater variability, DCIS grade, growth pattern and mitotic activity were 
associated with the risk of subsequent ipsilateral invasive breast cancer after DCIS in patients treated 
with BCS without radiotherapy.  A semi-quantitative grading system incorporating and separately 
evaluating nuclear pleomorphism, growth pattern and mitotic activity, analogue to IBC grading, may 
improve the reliability and prognostic value of these histopathological features. 
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Supplementary Material 
 
This is a .pdf file containing: 
 
Supplementary methods. This file gives additional information regarding rater selection, participation 
and the scoring process of the reliability study.  
Supplementary Table 1. Clinical characteristics of included and excluded patients for iIBC risk analysis.  
Supplementary Table 2. Number of scores per slide and agreement with the majority opinion per 
histopathological feature. This table gives background information about the majority opinion used in 
the analysis of subsequent iIBC risk after DCIS, on how many scores and on what agreement is the 
majority opinion based on, per histopathological feature.  
Supplementary Table 3. Characteristics of raters participating in the study.  
Supplementary Table 4. Associations of clinicopathological characteristics with subsequent iIBC in 
univariable analysis.  
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Figure Legends  
 
Fig. 1  Flow diagram for patient selection and exclusions  
Subcohort = randomly selected patient group; outside subcohort = patients who developed 
subsequent ipsilateral invasive breast cancer not included in the subcohort; iIBC = ipsilateral invasive 
breast cancer; a 2 outside subcohort patients developed invasive breast cancer after a mastectomy was 
performed during follow-up, for other reasons than iIBC. 
 
Fig. 2  Kaplan-Meier curve illustrating iIBC incidence after diagnosis of DCIS treated by BCS alone 
GP = growth pattern; other = flat epithelial atypia, clinging and (micro)papillary growth pattern   
The red dashed reference line depicts the maximum reached incidence in patients with DCIS grade 3 
with a cribriform/solid growth pattern treated with BCS+RT. 
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Table 1. Agreement, Gwet’s AC2 (GAC2) and Krippendorff’s alpha (KA) coefficients per histopathological feature 
Histopathological feature Agreement, % 95%CI, % GAC2 95%CI  KA  95%CI  
Grade (1, 2 or 3)  76.4 75.27-77.52 0.52 0.50-0.55 0.34 0.30-0.39 
Grade (1 versus 2+3) 83.5 81.33-85.68 0.78 0.74-0.82 0.35 0.28-0.42 
Grade (1+2 versus 3) 69.3 66.94-71.63 0.43 0.38-0.49 0.34 0.29-0.38 
Grade (low versus high) 72.8 70.54-75.12 0.52 0.47-0.57 0.38 0.32-0.44 
Dominant growth pattern  84.8 82.58-86.97 0.78 0.75-0.82 0.44 0.37-0.51 
Calcifications 81.1 78.81-83.40 0.70 0.65-0.75 0.49 0.43-0.54 
Necrosis 81.4 79.12-83.64 0.70 0.66-0.75 0.47 0.41-0.53 
Mitotic activity 78.5 76.12-80.97 0.70 0.65-0.74 0.24 0.19-0.29 
Periductal fibrosis  
(absent, subtle or prominent 
presence) 
70.9 69.71-72.13 0.37 0.34-0.39 0.25 0.22-0.29 
Periductal fibrosis  
(present versus absent) 
71.2 68.82-73.48 0.53 0.48-0.58 0.23 0.18-0.28 
Type of periductal fibrosis  
(if present) 
70.5 67.57-73.37 0.50 0.44-0.57 0.26 0.21-0.31 
Lymphocytic infiltrate 
(absent, subtle or prominent 
presence) 
77.1 75.82-78.36 0.50 0.47-0.53 0.42 0.38-0.47 
Lymphocytic infiltrate 
(present versus absent) 
73.0 70.51-75.40 0.51 0.45-0.56 0.38 0.33-0.43 
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GAC2 = Gwet’s AC2; KA = Krippendorff’s alpha; weighted analysis was performed for ordinal features with more than 2 categories using linear weights (grade 
1-3, periductal fibrosis and lymphocytic infiltrate); CI = Confidence Interval 
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Table 2. Clinicopathological characteristics of the study population  
Number of DCIS patients (%)   
 
All patients with iIBC  
137* 
Subcohort  
215** 
Treatment 
  
BCS+RT 42 (30.7) 128 (59.5) 
BCS alone 95 (69.3) 87 (40.5) 
Age at DCIS diagnosis, years, 
median (iqr) 57.5 (53.1-63.6) 58.4 (53.4-64.0) 
Age at DCIS diagnosis, years 
(quartiles) 
  
≥49.5 - ≤53.4 37 (27.0) 54 (25.1) 
>53.4 - ≤58.2  36 (26.3) 50 (23.3) 
>58.2 - ≤63.8  32 (23.4) 56 (26.1) 
>63.8 - ≤75.6 32 (23.4) 55 (25.6) 
Period of DCIS diagnosisa 
  
1993 - 1998 76 (55.5) 82 (38.1) 
1999 - 2004 61 (44.5) 133 (61.9) 
Median follow-up, years (iqr) 
 
11.2 (8.6-14.1) 
Time to iIBC, years, median (iqr) 5.3 (3.3-7.6) 
 
Grade (1,2 or 3)b 
  
Grade 1 10 (7.3) 23 (10.7) 
Grade 2 67 (48.9) 115 (53.5) 
Grade 3 60 (43.8) 77 (35.8) 
Grade (low versus high) 
  
Low grade 31 (22.6) 60 (27.9) 
High grade 106 (77.4) 155 (72.1) 
Dominant growth patternc 
  
FEAd, clinging, (micro)papillary 14 (10.2) 34 (15.9) 
Cribriform, solid 123 (89.8) 180 (84.1) 
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Table 2 continued.   
Number of DCIS patients (%)   
 
All patients with iIBC  
137* 
Subcohort  
215** 
Calcifications 
  
Present 103 (75.2) 168 (78.1) 
Absent 34 (24.8) 47 (21.9) 
Necrosis 
  
Present 109 (79.6) 167 (77.7) 
Absent 28 (20.4) 48 (22.3) 
Mitoses 
  
Sparse 114 (83.2) 198 (92.1) 
Many 23 (16.8) 17 (7.9) 
Periductal fibrosis 
  
Absent 28 (20.4) 41 (19.1) 
Subtle 73 (53.4) 102 (47.4) 
Prominent 36 (26.3) 72 (33.5) 
Type of periductal fibrosise 
  
Sclerotic 80 (73.4) 133 (76.4) 
Myxoid 29 (26.6) 41 (23.6) 
Lymphocytic infiltrate 
  
Absent 38 (27.7) 77 (35.8) 
Subtle 65 (47.5) 89 (41.4) 
Prominent 34 (24.8) 49 (22.8) 
 
subcohort = randomly selected patient group; * six out of all patients with iIBC developed breast cancer 
metastases only; ** sixteen patients from the subcohort developed an iIBC and four developed breast 
cancer metastases only; iqr = interquartile range; a 1993-1998 reflecting part of the screening 
implementation phase and 1999-2004 reflecting full nationwide coverage;  
b histopathological DCIS features were based on the majority opinion; c in one patient growth pattern 
was scored as not assessable by all raters and was therefore excluded (n included patients = 331); FEA 
= flat epithelial atypia; d  there is controversy about whether to consider FEA as a subtype of DCIS 
(clinging, monomorphic type) or not, therefore this option was included as possible DCIS growth 
pattern; e for type of fibrosis patients were only included when according to the majority opinion 
periductal fibrosis was present, either subtle or prominent (n included patients = 268) 
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Table 3. Associations of histopathological features with subsequent iIBC in multivariable analysis 
Histopathological feature BCS alone BCS+RT Treatment interaction 
 n HR (95%CI) P n HR (95%CI) P P 
Grade (1+2 versus 3)       0.017 
1+2 107 (52) REF  104 (28) REF   
3 62 (43) 2.64 (1.35-5.14) 0.005 58 (14) 0.79 (0.38-1.62) 0.52  
Dominant growth pattern       0.022 
FEA/clinging/(micro)papillary 23 (7) REF  23 (7) REF   
Cribriform/Solid 146 (88) 3.70 (1.34-10.23) 0.012 139 (35) 0.77 (0.32-1.85) 0.56  
 
n = total number (number of patients with subsequent iIBC); HR = Hazard Ratio; CI = Confidence Interval; P = P value; REF = reference; FEA = flat epithelial 
atypia 
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Fig.1. 
 
  
DCIS treated by BCS+/-RT in 1993-2004 
n = 2767 
  
n = 534 
Subcohort 
n = 357 
Outside subcohort  
n = 177 
No (pure) DCIS     n = 
7 
Uncertainty on iIBC occurrence   n = 
5 
Other         n = 4 
 
Excluded after pathology report review  
n = 16 
Patients eligible for study (n = 507) 
Material received  
DCIS not confirmed     n = 6 
No (pure) DCIS       n = 
11 
Excluded after internal slide review  
n = 18 
 
Patients included in reliability study (n = 
353)  
 
Final analysis of reliability (n = 342) 
      Final analysis of iIBC risk (n = 332)
  
   n = 215                              n = 117 
Excluded after external slide review  
n = 3 
Excluded after external slide reviewa 
n = 5 
No (pure) DCIS     n = 
9 
Other      n = 2 
 
Excluded after pathology report review  
n = 11  
DCIS not confirmed    n = 22 
No (pure) DCIS     n = 
36 
Excluded after internal slide review  
n = 58  
 
Excluded after external slide review  
n = 8 
Excluded after external slide review  
n = 5 
 n = 286 (83%)                     n = 143 (89%)  
  n = 220                    n = 122  
  n = 228                   n = 125  
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Fig. 2. 
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Supplementary methods 
Rater selection and participation 
To ensure a mixed group of raters in terms of expertise and experience, a dual selection 
approach was undertaken. Members of the European Working Group for Breast Screening 
Pathology, a working group set up in 1993 in order to make the practice of breast pathology 
more uniform and considered breast pathology experts, were invited to participate by email. 
Twenty-two members agreed to participate and 17 completed the study.  
All participants of the ‘7th Dutch Breast Pathology Course’ (November 2018, Amsterdam; 31 
pathologists and 3 residents) with different levels of expertise were also invited to participate 
in the study. Nineteen pathologists and 2 residents completed the study, for which the first 
received CME accreditation as compensation.  
After study-closure all raters who completed the study received personal feedback by 
providing an overview comparing their scores with those from the group.  
Study sets  
To reduce the workload while ensuring enough ratings per case for subsequent analysis, each 
rater was assigned a personal study set, including in total 146 cases. The study sets were 
composed in two steps. Firstly, 100 cases were randomly selected from the total cohort of 353 
cases and assigned to the study sets of all raters. Secondly, for each rater individually 46 cases 
out of the remaining 253 cases not yet assigned, were randomly selected and added to their 
study set.  
Fifty out of the 100 cases, which were assigned to all raters, were placed in the beginning of 
the study set and the other fifty were randomly distributed amongst the remaining cases. 
Raters were aware of a presumed DCIS diagnosis in this study and were not restricted in 
scoring time (starting date 15/10/2018 - closing date 08/02/2019). 
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DCIS scoring form 
1. DCIS present? (if not, please give 
the diagnosis under comments) 
o Yes 
o No 
o Not assessable 
1. Dominant growth pattern? 
o Not assessable 
o FEA 
o Clinging 
o (Micro)papillary 
o Cribriform 
o Solid 
2. DCIS grade? (1/2/3) 
o Not assessable 
o Well differentiated 
o Moderately differentiated 
o Poorly differentiated 
3. DCIS grade? (low/high) 
o Not assessable 
o Low grade 
o High grade 
4. Necrosis present? 
o Not assessable 
o Absent 
o Present 
 
5. Calcification present? 
o Not assessable 
o Absent 
o Present 
6. Frequency of mitoses? 
o Not assessable 
o Sparse 
o Many 
7. Periductal fibrosis present? 
o Not assessable 
o Absent 
o Subtle 
o Prominent 
8. Only if fibrosis is present: what is 
the (dominant) type of stroma? 
o Not assessable 
o Sclerotic 
o Myxoid 
9. Lymphocytic infiltrate present? 
o Not assessable 
o Absent 
o Subtle 
o Prominent 
 
         Comments (other diagnosis or 
otherwise) 
 
1 = well differentiated/2 = moderately differentiated/3 = poorly differentiated; FEA = flat 
epithelial atypia; There is controversy about whether to consider FEA as a subtype of DCIS 
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(clinging, monomorphic type) or not, therefore this option was included as possible DCIS 
growth pattern. 
 
 
 
DCIS Interobserver Study – rater background questionnaire 
1. Your email address a 
2. In which country are you working? 
3. In which hospital/pathology lab are you working? 
4. Where did you receive your pathology training? (hospital/place/country) 
5. How many years are you working as a pathologist? 
0-5 years 
6-10 years 
11-15 years 
16-20 years 
>20 years 
6. How many years are you looking at breast cases? 
0-5 years 
6-10 years 
11-15 years 
16-20 years 
>20 years 
7. Do your colleagues consider you an expert in breast pathology? 
 Yes 
 No 
8. How many pathologists are working in your lab? 
9. How many pathologists are looking at breast cases in your lab? 
10. How many breast cases are seen annually in your lab (estimate, biopsies + surgical 
specimens) 
11. Do you look at revision or consult cases? 
 Yes 
 No 
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12. Which DCIS grading system do you use in daily practice? 
 Holland et al (1994; 3-tiered; based on nuclear grade and cell polarization)  
Pinder et al (2010; 4-tiered; very high = high nuclear grade + >50% solid growth & 
comedo-necrosis) 
Van Nuys (1995; 3-tiered; high grade, non-high grade with necrosis, non-high grade 
without necrosis) 
Poller et al. (1994; 2-tiered; pure comedo, non comedo) 
Lagios (1990; 3-tiered; based on nuclear features & frequency of mitoses) 
College of American Pathologists Guidelines 
WHO 
Intuition 
Other:  
13. In case of a heterogeneous DCIS, how did you grade in this study? 
 I gave the highest grade 
 I gave the predominant grade 
 Other: 
14. Comments regarding your interpretation of specific items in the study 
15. How would you rate the slide viewing platform ‘Slide Score’? 
16. Comments/feedback for Slide Score 
 
A questionnaire was sent to all 38 raters who finished their complete study set with questions 
regarding their working environment, experience and their method of DCIS grading. Thirty-
five pathologists and 2 residents completed the questionnaire.  
a Required 
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Supplementary Table 1. Clinical characteristics of included and excluded patients for iIBC risk analysis   
 
Subcohort patients 
 
Patients outside subcohort with subsequent 
iIBC 
 
  
Included patients n 
(%) 215 (60.2) 
Excluded patients n 
(%) 142 (39.8) Pa 
Included patients n 
(%) 117 (66.1) 
Excluded patients n 
(%) 60 (33.9) Pa 
Patient group   
  
  
  
Subcohort, no iIBC 195 (90.7) 131 (92.3) 
 
  
  
Subcohort, iIBC 20 (9.3) 11 (7.8) 0.61   
  
Treatment   
  
  
  
BCS+RT 128 (59.5) 77 (54.2) 
 
34 (29.1) 24 (40.0) 
 
BCS alone 87 (40.5) 65 (45.8) 0.32 83 (70.9) 36 (60.0)  0.14 
Age at DCIS diagnosis, 
years, median (iqr) 
58.4 (53.4-64.0) 58.3 (53.3-64.2) 0.68 57.5 (53.2-63.6) 59.0 (54.5-62.0)  0.63 
Age at DCIS diagnosis, 
years 
(quartiles)   
  
  
  
≥49.5 - ≤53.4 54 (25.1) 38 (26.8) 
 
30 (25.6) 13 (21.7) 
 
>53.4 - ≤58.3 53 (24.7) 33 (23.2) 
 
32 (27.4) 15 (25.0) 
 
>58.3 - ≤63.7  53 (24.7) 31 (21.8) 
 
27 (23.1) 23 (38.3) 
 
>63.7 - ≤75.6 55 (25.6) 40 (28.2) 0.88 28 (23.9) 9 (15.0)  0.16 
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Period of DCIS diagnosisb   
  
  
  
1993 – 1998 82 (38.1) 58 (40.9) 
 
63 (53.9) 43 (71.7) 
 
1999 – 2004 133 (61.9) 84 (59.2) 0.61 54 (46.2) 17 (28.3)  0.022 
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Subcohort = randomly selected patient group; n = number; P =  P value; a For categorical variables the P value was calculated by a chi-square test, 
for age at diagnosis by a Wilcoxon rank-sum test; iIBC = ipsilateral invasive breast cancer; iqr = interquartile range; b 1993-1998 reflecting part of 
the screening implementation phase and 1999-2004 reflecting full nationwide coverage 
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Supplementary Table 2. Number of scores per slide and agreement with the 
majority opinion per histopathological feature  
  n of scores per slide 
Agreement with the 
majority opinion score (%) 
 
Histopathological feature 
Mea
n Median (iqr) Mean Median (iqr) 
 
Grade (1,2 or 3) 14 7 (6-32) 70.1 69.4 (57.1-83.3) 
 
Grade (1 versus 2+3) 14 7 (6-32) 89.8 97.3 (83.3-100)  
Grade (1+2 versus 3) 14 7 (6-32) 79.4 83.3 (66.7-100) 
 
Grade (low versus high) 14 7 (6-30) 83.0 85.3 (71.4-100) 
 
Dominant growth patterna     15 7 (6-32) 90.4 100 (83.3-100) 
 
Calcifications 15 7 (6-32) 88.2 97.1 (80.0-100) 
 
Necrosis 15 7 (6-33) 88.2 95.4 (80.0-100) 
 
Mitotic activity 13 7 (6-29) 86.4 93.8 (75.0-100) 
 
Periductal fibrosis (absent, 
subtle or prominent 
presence) 
15 7 (6-32) 65.1 62.5 (54.1-75.0) 
 
Periductal fibrosis  
(present versus absent) 
15 7 (6-32) 81.6 83.3 (71.4-100) 
 
Type of periductal fibrosisb 12 6 (5-24) 81.7 83.3 (66.7-100) 
 
Lymphocytic infiltrate 
(absent, subtle or prominent 
presence) 
15 7 (6-31) 71.1 67.6 (57.1-83.3) 
 
Lymphocytic infiltrate  
(present versus absent) 
15 7 (6-31) 82.4 83.8 (66.7-100) 
 
n = number; iqr = interquartile range; a  in one patient growth pattern was scored as not 
assessable by all raters and was therefore excluded (n included patients = 341); b for type of 
fibrosis patients were only included when according to the majority opinion periductal fibrosis 
was present, either subtle or prominent (n included patients = 276) 
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Supplementary Table 3. Characteristics of raters participating in the 
studya,b 
Experience, years n (%) 
0-5  5 (15.2) 
6-10  2 (6.1) 
11-15  3 (9.1) 
16-20  5 (15.2) 
> 20  18 (54.6) 
Country of work 
 
the Netherlands 17 (48.6) 
Europe, other  18 (51.4) 
EWGBSP-member 
 
Yes 17 (47.2) 
No 19 (52.8) 
Considered expert in breast pathology by 
colleagues 
 
Yes 30 (88.2) 
No 4 (11.8) 
Experience with breast revision/consult cases 
 
Yes 26 (74.3) 
No 9 (25.7) 
DCIS grading system used 
 
WHO[1] 9 (25.0) 
Holland[2] 10 (27.8) 
Van Nuys[3] 4 (11.1) 
WHO & Van Nuys 4 (11.1) 
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WHO & Holland 2 (5.6) 
WHO & Holland & Lagios[4] 1 (2.8) 
WHO & CAP[5] 1 (2.8) 
Lagios 1 (2.8) 
Pinder[6]  1 (2.8) 
Other 3 (8.3) 
Grading in case of heterogeneous DCIS  
 
Highest grade 33 (94.3) 
Predominant grade  2 (5.7) 
Supplementary Table 3 continued.  
Characteristics of the raters’ laboratories  
 
n of pathologists, median (iqr) 13 (8-15) 
n of breast pathologists, median (iqr) 4 (3-5) 
Laboratory specializationc, median (iqr) 2.6 (1.8-4.6) 
n of breast cases seen annually, median (iqr) 1200 (600-2000) 
  
a
 the questionnaire was not filled in (completely) by all raters, percentages 
are based on the responders; b Residents are included only in questions 
regarding their grading of DCIS 
n = number; iqr = interquartile range; EWGBSP = members of the 
European Working Group for Breast Screening Pathology; c Laboratory 
specialization = number of pathologists in rater’s laboratory/number of 
breast pathologists in rater’s laboratory 
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Supplementary Table 4. Associations of clinicopathological characteristics with subsequent iIBC in univariable analysis 
Clinicopathological 
characteristic 
All patients BCS alone BCS+RT  Interaction 
n HR (95% CI) P n HR (95% CI) P n HR (95% CI) P P 
Grade (1,2 or 3)a 
         
  
1 31 (10) REF 
 
21 (8) REF 
 
10 (2) REF 
 
  
2 172 (67) 1.28 (0.58-2.83) 0.54 84 (43) 1.61 (0.63-4.08) 0.32 88 (24) 1.39 (0.27-7.15) 0.69 0.94 
3 129 (60) 1.69 (0.75-3.80) 0.20 65 (44) 3.19 (1.21-8.37) 0.019 64 (16) 1.10 (0.20-5.89) 0.91 0.33  
Grade (1 versus 2+3) 
         
  
1 30 (10) REF 
 
21 (8) REF 
 
9 (2) REF 
 
  
2+3 
302 
(127) 
1.35 (0.62-2.91) 
0.45 149 (87) 
2.15 (0.88-5.22) 
0.092 153 (40) 
0.98 (0.19-5.14) 
0.99 0.50  
Grade (1+2 versus 3) 
         
  
1+2 211 (80) REF 
 
107 (52) REF 
 
104 (28) REF 
 
  
3 121 (57) 1.41 (0.90-2.20) 0.13 63 (43) 2.34 (1.24-4.42) 0.009 58 (14) 0.74 (0.35-1.56) 0.42 0.028 
Grade (low versus high) 
         
  
Low 87 (31) REF 
 
54 (27) REF 
 
33 (4) REF 
 
  
High 
245 
(106) 
1.33 (0.81-2.20) 
0.26 116 (68) 
1.47 (0.79-2.76) 
0.23 129 (38) 
2.68 (0.88-8.21) 
0.084 0.34 
Dominant growth patternb 
         
  
FEA/clinging/(micro)papillary 46 (14) REF 
 
23 (7) 
  
23 (7) REF 
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Cribriform/solid 
285 
(123) 
1.76 (0.92-3.36) 
0.087  146 (88) 
3.44 (1.33-8.91) 
0.011 139 (35) 
0.70 (0.29-1.72) 
 0.44 0.023 
 
 
Supplementary Table 4 continued. 
Clinicopathological 
characteristic 
All patients   BCS alone   BCS+RT   Interaction 
n HR (95% CI) P n HR (95% CI) P n HR (95% CI) P P 
Calcifications 
         
  
Present 
256 
(103) 
REF 
 
131 (71) 
REF 
 
125 (32) 
REF 
 
  
Absent 76 (34) 1.23 (0.75-2.04) 0.41 39 (24) 1.31 (0.65-2.65) 0.45 37 (10) 1.13 (0.51-2.53) 0.77 0.76 
Necrosis 
         
  
Present 
260 
(109) 
REF 
 
126 (72) 
REF 
 
134 (37) 
REF 
 
  
Absent  72 (28) 0.87 (0.52-1.46) 0.59 44 (23) 0.80 (0.41-1.56) 0.51 28 (5) 0.60 (0.22-1.65) 0.32 0.59  
Mitotic activity 
         
  
Sparse  
294 
(114) 
REF 
 
141 (74) 
REF 
 
153 (40) 
REF 
 
  
Many 38 (23) 2.42 (1.20-4.91) 0.014 29 (21) 2.53 (1.05-6.11) 0.038 9 (2) 0.79 (0.15-4.15) 0.78 0.21  
Periductal fibrosisa 
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Absent 64 (28) REF 
 
42 (24) REF 
 
22 (4) REF 
 
  
Subtle 165 (73) 1.02 (0.58-1.78) 0.95 84 (48) 1.01 (0.50-2.05) 0.98 81 (25) 1.98 (0.63-6.20) 0.24 0.33  
Prominent 103 (36) 0.70 (0.38-1.31) 0.27 44 (23) 0.84 (0.36-1.91) 0.67 59 (13) 1.29 (0.39-4.30) 0.68 0.56  
Periductal fibrosis present/ 
absent 
         
  
Present (subtle/prominent) 
275 
(113) 
REF 
 
134 (75) 
REF 
 
141 (38) 
REF 
 
  
Absent  57 (24) 1.06 (0.61-1.84) 0.84 36 (20) 0.97 (0.48-1.96) 0.94 21 (4) 0.67 (0.22-2.02) 0.48 0.56  
 
       
Supplementary Table 4 continued.       
Clinicopathological 
characteristic 
All patients  BCS alone BCS+RT   Interaction 
n HR (95% CI) P n HR (95% CI) P n HR (95% CI) P P 
Type of periductal fibrosisc 
         
  
Sclerotic  202 (80) REF 
 
101 (54) REF 
 
101 (26) REF 
 
  
Myxoid 66 (29) 1.29 (0.74-2.24) 0.37 27 (17) 2.23 (0.86-5.76) 0.099 39 (12) 1.18 (0.53-2.62) 0.68 0.34 
Lymphocytic infiltratea 
         
  
Absent 108 (38) REF 
 
58 (30) REF 
 
50 (8) REF 
 
  
Subtle 144 (65) 1.48 (0.90-2.44) 0.12 77 (42) 1.11 (0.58-2.14) 0.75 67 (23) 2.74 (1.12-6.69) 0.027 0.11  
Prominent 80 (34) 1.35 (0.75-2.41) 0.32 35 (23) 1.91 (0.80-4.54) 0.14 45 (11) 1.56 (0.58-4.21) 0.38 0.79 
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Lymphocytic infiltrate 
present/absent 
         
  
Present (subtle/prominent) 
227 
(100) 
REF 
 
113 (66) 
REF 
 
114 (34) 
REF 
 
  
Absent  105 (37) 0.71 (0.45-1.13) 0.15 57 (29) 0.73 (0.39-1.35) 0.31 48 (8) 0.50 (0.22-1.16) 0.11 0.46  
Age at diagnosis, years 
(quartiles) 
 
 
  
 
  
 
 
  
≥49.5 - ≤53.4 84 (37) REF 
 
 38 (20) REF 
 
 46 (17) REF 
 
  
>53.4 - ≤58.2  82 (36) 0.97 (0.53-1.76) 0.92  43 (24) 1.12 (0.47-2.64) 0.80  39 (12) 0.73 (0.30-1.79) 0.49 0.51   
>58.2 - ≤63.8 83 (32) 0.81 (0.44-1.48) 0.49  43 (26) 1.24 (0.53-2.90) 0.61  40 (6) 0.33 (0.11-0.92) 0.035 0.048 
>63.8 - ≤75.6 83 (32) 0.84 (0.46-1.53) 0.57  46 (25) 1.02 (0.45-2.34) 0.96  37 (7) 0.46 (0.17-1.26) 0.13 0.20  
 
Supplementary Table 4 continued. 
Clinicopathological 
characteristic 
All patients  BCS alone  BCS+RT   Interaction 
n HR (95% CI) P n HR (95% CI) P n HR (95% CI) P P 
Age at diagnosis (cont.)  0.98 (0.95-1.02) 0.38  1.00 (0.96-1.05) 0.90  0.93 (0.86-1.00) 0.053 0.079 
Period of DCIS diagnosis 
         
  
1993 – 1998 145 (76) REF 
 
104 (63) REF 
 
41 (13) REF 
 
  
1999 – 2004 187 (61) 0.61 (0.39-0.96) 0.032 66 (32) 0.75 (0.41-1.37) 0.35 121 (29) 1.44 (0.58-3.57) 0.44 0.66 
Treatment 
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BCS+RT / 0-5 years 162 (14)  REF 
 
  
  
  
  
  
BCS+RT / >5 years 142 (28) 0.51 (0.24-1.12) 0.093    
  
  
  
  
BCS alone / 0-5 years 170 (43) 4.80 (2.49-9.24) 0.000   
  
  
  
  
BCS alone / >5 years 118 (52) 2.47 (1.42-4.30) 0.001   
  
  
  
  
 
  Pheterogeneity  0.000   
  
  
  
  
n = total number (number of patients with subsequent iIBC); HR = Hazard Ratio; CI = Confidence Interval; P = P value; Interaction = interaction 
with treatment;  REF = reference; cont. =  Continuous; a Recategorizations of grade, periductal fibrosis, and lymphocytic infiltrate may have led 
to small differences in the majority opinion (for example when considering the histopathological feature grade 1-3 with a distribution of grade 
1 -30%, grade 2 -30% and grade 3 -40% with grade 3 as majority opinion will lead to a categorical shift when recategorizing grade 1-3 into grade 
1+2 versus 3 with an adjusted distribution of grade 1 or 2 - 60% and grade 3 -40% with grade 1+2 as majority opinion); b in one patient growth 
pattern was scored as not assessable by all raters and was therefore excluded (n included patients = 331); c for type of fibrosis patients were 
only included when according to the majority opinion periductal fibrosis was present, either subtle or prominent (n included patients = 268) 
49 
 
References 
1.  Lakhani SR, Ellis. I.O., Schnitt SJ, Tan PH, van de Vijver MJ. WHO classification of 
tumours of the breast. 4th ed. Lyon: International Agency for Research on Cancer; 
2012.  
2.  Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, Van de Vijver MJ, et al. Ductal 
carcinoma in situ: A proposal for a new classification. Semin Diagn Pathol. 
1994;11(3):167–80.  
3.  Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED, et al. 
Prognostic classification of breast ductal carcinoma-in-situ. Lancet. 
1995;345(8958):1154–7.  
4.  Lagios MD. Duct carcinoma in situ. Pathology and treatment. Surg Clin North Am. 
1990;70(4):873–83.  
5.  College of American pathologists [Internet]. Available from: 
https://documents.cap.org/protocols/cp-breast-dcis-18protocol-4100.pdf 
6.  Pinder SE, Duggan C, Ellis IO, Cuzick J, Forbes JF, Bishop H, et al. A new pathological 
system for grading DCIS with improved prediction of local recurrence: Results from 
the UKCCCR/ANZ DCIS trial. Br J Cancer. 2010;  
 
 
